These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 33441146

  • 21. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.
    Calzetta L, Di Marco F, Blasi F, Cazzola M, Centanni S, Micheletto C, Rossi A, Rogliani P.
    Pulm Pharmacol Ther; 2019 Dec; 59():101855. PubMed ID: 31639476
    [Abstract] [Full Text] [Related]

  • 22. Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD.
    Huang WC, Chen CY, Liao WC, Wu BR, Chen WC, Tu CY, Chen CH, Cheng WC.
    J Clin Med; 2022 Dec 01; 11(23):. PubMed ID: 36498738
    [Abstract] [Full Text] [Related]

  • 23. Comparison of Clinical Outcomes Among Different Fixed-Dose Combinations of Long-Acting Muscarinic Antagonists and Long-Acting β2-Agonists in Patients With COPD.
    Weng CF, Wu CC, Wu MH, Lin FJ.
    Chest; 2023 Apr 01; 163(4):799-814. PubMed ID: 36442662
    [Abstract] [Full Text] [Related]

  • 24. [LAMA/LABA fixed dose combination for treatment of COPD].
    Kuwahira I.
    Nihon Rinsho; 2016 May 01; 74(5):820-6. PubMed ID: 27254953
    [Abstract] [Full Text] [Related]

  • 25. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
    Ferguson GT, Darken P, Ballal S, Siddiqui MK, Singh B, Attri S, Holmgren U, de Nigris E.
    Adv Ther; 2020 Jun 01; 37(6):2956-2975. PubMed ID: 32335859
    [Abstract] [Full Text] [Related]

  • 26. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR.
    Int J Chron Obstruct Pulmon Dis; 2017 Jun 01; 12():997-1008. PubMed ID: 28392684
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
    ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R.
    Int J Chron Obstruct Pulmon Dis; 2014 Jun 01; 9():1133-44. PubMed ID: 25342898
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.
    Ferguson GT, Fležar M, Korn S, Korducki L, Grönke L, Abrahams R, Buhl R.
    Adv Ther; 2015 Jun 01; 32(6):523-36. PubMed ID: 26112656
    [Abstract] [Full Text] [Related]

  • 29. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting.
    Steinmetz KO, Abenhardt B, Pabst S, Hänsel M, Kondla A, Bayer V, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2019 Jun 01; 14():1441-1453. PubMed ID: 31308649
    [Abstract] [Full Text] [Related]

  • 30. Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD.
    Gong Y, Lv Y, Liu H, Zheng Q, Li L.
    Ther Adv Respir Dis; 2022 Jun 01; 16():17534666211066068. PubMed ID: 35001708
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD.
    Banerji D, Mahler DA, Hanania NA.
    Expert Rev Respir Med; 2016 Jul 01; 10(7):767-80. PubMed ID: 27223863
    [Abstract] [Full Text] [Related]

  • 32. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
    Kerwin EM, Kalberg CJ, Galkin DV, Zhu CQ, Church A, Riley JH, Fahy WA.
    Int J Chron Obstruct Pulmon Dis; 2017 Jul 01; 12():745-755. PubMed ID: 28280319
    [Abstract] [Full Text] [Related]

  • 33. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
    Ramadan WH, Kabbara WK, El Khoury GM, Al Assir SA.
    Int J Chron Obstruct Pulmon Dis; 2015 Jul 01; 10():2347-56. PubMed ID: 26586940
    [Abstract] [Full Text] [Related]

  • 34. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.
    Driessen MT, Whalen J, Seewoodharry Buguth B, Vallejo-Aparicio LA, Naya IP, Asukai Y, Alcázar-Navarrete B, Miravitlles M, García-Río F, Risebrough NA.
    Respir Res; 2018 Nov 20; 19(1):224. PubMed ID: 30458866
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
    Dahl R, Jadayel D, Alagappan VK, Chen H, Banerji D.
    Int J Chron Obstruct Pulmon Dis; 2013 Nov 20; 8():501-8. PubMed ID: 24159259
    [Abstract] [Full Text] [Related]

  • 36. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
    Beeh KM, Westerman J, Kirsten AM, Hébert J, Grönke L, Hamilton A, Tetzlaff K, Derom E.
    Pulm Pharmacol Ther; 2015 Jun 20; 32():53-9. PubMed ID: 25956072
    [Abstract] [Full Text] [Related]

  • 37. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD.
    Albertson TE, Bowman WS, Harper RW, Godbout RM, Murin S.
    Int J Chron Obstruct Pulmon Dis; 2019 Jun 20; 14():1251-1265. PubMed ID: 31239659
    [Abstract] [Full Text] [Related]

  • 38. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review.
    Rogliani P, Calzetta L, Braido F, Cazzola M, Clini E, Pelaia G, Rossi A, Scichilone N, Di Marco F.
    Int J Chron Obstruct Pulmon Dis; 2018 Jun 20; 13():3115-3130. PubMed ID: 30323582
    [Abstract] [Full Text] [Related]

  • 39. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
    Ichinose M, Taniguchi H, Takizawa A, Grönke L, Loaiza L, Voß F, Zhao Y, Fukuchi Y.
    Int J Chron Obstruct Pulmon Dis; 2016 Jun 20; 11():2017-27. PubMed ID: 27621608
    [Abstract] [Full Text] [Related]

  • 40. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.
    Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R.
    Int J Chron Obstruct Pulmon Dis; 2017 Jun 20; 12():1325-1337. PubMed ID: 28496316
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.